Key result
Low-dose ASA benefits men 40 to 69 but lacks primary prevention value in higher-risk adults.
Why the study?
To address modern approaches and management tactics for primary and secondary prevention of atherosclerotic cardiovascular disease with low-dose acetylsalicylic acid.
Does low-dose acetylsalicylic acid (75-150 mg/day) reduce the risk of cardiovascular disease in primary and secondary prevention?
Does low-dose acetylsalicylic acid (75-150 mg/day) reduce the risk of cardiovascular disease in primary and secondary prevention?
Low-dose aspirin has limited benefit for primary prevention in adults over 40 with increased CVD risk, but may be effective in men aged 40-69 without high bleeding risk.
Limits aspirin for primary prevention in higher-risk adults ≥40; leaves open targeted use in men 40-69 without bleeding risk.
The article is devoted to an urgent problem - primary and secondary prevention of atherosclerotic cardiovascular diseases. Modern approaches to management tactics depending on age and the appointment of antiplatelet therapy with acetylsalicylic acid in low doses from 75 to 150 mg/day are presented. At the same time, the relatively high effectiveness of the use of ASA for primary prevention in men 40-69 years old without an increased risk of bleeding from the gastrointestinal tract is shown. Low doses of ASA provide little benefit in reducing the risk of CVD in people 40 years and older, when there is no history of CVD, but at the same time they are at increased risk of CVD.
No takes yet. Share an insight, caveat, or question.
Oynotkinova et al. (2023) conducted a review in Atherosclerotic cardiovascular disease. Acetylsalicylic acid (ASA) was evaluated. Low-dose acetylsalicylic acid (75-150 mg/day) benefits men aged 40-69 without high bleeding risk, but offers little primary prevention benefit for individuals ≥40 years with increased CVD risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: